Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Toshiki Masuishi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

T. Masuishi1, T. Suzuki2, Y. Sukawa2, C.K. Imamura3, H. Satake4, Y. Kumekawa5, S. Funakoshi6, M. Kotaka7, Y. Horie8, S. Kawai9, H. Okuda10, T. Terazawa11, C. Kondoh12, K. Kato13, K. Yoshimura14, H. Ishikawa15, Y. Hamamoto16, N. Boku17, T. Kanai2, H. Takaishi16

Author affiliations

  • 1 Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 2 Division Of Gastroenterology And Hepatology, Department Of Internal Medicine, Keio University School of Medicine, 160-8582 - Tokyo/JP
  • 3 Department Of Clinical Pharmacokinetics And Pharmacodynamics, Keio University School of Medicine, 160-8582 - Tokyo/JP
  • 4 Department Of Medical Oncology, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 5 Department Of Gastroenterology, Saitama cancer Center, 362-0806 - Saitama/JP
  • 6 Department Of Internal Medicine, Division Of Medical Oncology, Tokyo Saiseikai Central Hospital, 108-0073 - Tokyo/JP
  • 7 Surgery, Sano Hospital-Gastrointestinal Cancer Centre, 655-0031 - Kobe/JP
  • 8 Department Of Clinical Oncology, St Marianna University School of Medicine, 216-8511 - Kawasaki city/JP
  • 9 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 10 Medical Oncology, Keiyukai Sapporo Hospital, Sapporo/JP
  • 11 Cancer Chemotherapy Center, Osaka Medical College, 569-8686 - Takatsuki/JP
  • 12 Department Of Medical Oncology, Toranomon Hospital, 105-8470 - Tokyo/JP
  • 13 Gastrointestinal Oncology Division, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 14 Innovative Clinical research Center, Kanazawa University Hospital, 920-8641 - Kanazawa/JP
  • 15 Department Of Molecular-targeting Cancer Prevention, Kyoto Prefectural University of Medicine, 41-0043 - Kyoto/JP
  • 16 Cancer Center, Keio University School of Medicine, 160-8582 - Tokyo/JP
  • 17 Gastrointesitnal Medical Onclogy, National Cancer Center Hospital, 104-0045 - Tokyo/JP
More

Resources

Abstract 2548

Background

Regorafenib is the first small-molecule multikinase inhibitor with survival benefit as a salvage line therapy for metastatic colorectal cancer (mCRC). However, severe toxicities often occur early and require dose reduction and/or interruption. To improve dose intensity and treatment outcome, we investigated regorafenib dose escalation strategy with low starting dose. The association between systemic exposure and tolerability was also analyzed.

Methods

In this phase II, single arm, multicenter study, we enrolled patients with refractory mCRC. Regorafenib was initiated at 120 mg/day. In patients who experienced neither hand-foot skin reaction nor grade ≥2 adverse reactions without dose reduction or interruption until day 15 in the first cycle, the dose of regorafenib was escalated to standard dose of 160 mg/day at day 15. The primary endpoint was disease control rate (DCR). With power of 80% and two-sided alpha of 5%, 67 patients were required to reject 30% of DCR expecting 45% of DCR. Serum concentrations of regorafenib and its active metabolites (M-2, N-oxide metabolite; M-5, N-oxide/N-desmethyl metabolite) at days 8, 15 and 22 in the first cycle were assessed.

Results

From September 2016 to December 2017, 68 patients were enrolled. The DCR was 32.4% (95% CI, 21.5-44.8) with no patients achieving complete or partial response. The dose of regorafenib was escalated to 160 mg at day 15 in only six patients of 39 patients without dose reduction or interruption until day 15. In 55 patients without dose reduction or interruption due to adverse reactions until day8, the serum concentrations of regorafenib at day 8 in the six patients whose dose was escalated to 160 mg were significantly lower than those in the other 49 patients (median, 3978 nM; range, 2487-13614 nM vs. 6951 nM; 2822-17621 nM; P = 0.028). The serum concentrations of sum of regorafenib and active metabolites (M-2 and M-5) at day 8 showed similar tendency (6582 nM; 2913-21388 nM vs. 11730 nM; 4596-33211 nM; P = 0.064).

Conclusions

This dose escalation strategy with low starting dose for regorafenib did not improve DCR. Lower systemic exposure was associated with better tolerability.

Clinical trial identification

Legal entity responsible for the study

Hiromasa Takaishi.

Funding

Keio University.

Editorial Acknowledgement

Disclosure

T. Masuishi: Honoraria: Bayer. H. Satake: Honoraria: Bayer, Chugai Pharma, Eli Lilly Japan, Merck Serono, Takeda, Taiho Pharmaceutical, Yakult Honsha. N. Boku: Investigator initiated trial funded by Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings